Bispecific antibody · Immune activation, directed at ENPP3 and CD3 (CD3E) · developed by Xencor
XmAb819 is a bispecific antibody that binds ENPP3, a type II transmembrane glycoprotein overexpressed on some tumor cells, and CD3 on T-cells. By cross-linking the two, it is intended to trigger a cytotoxic T-lymphocyte response against ENPP3-expressing cells. It is being studied in clear cell renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05433142 | Phase 1 | Clear Cell Renal Cell Carcinoma | Recruiting | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear Cell Renal Cell Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →